What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for hiv-serodiscordant couples

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 5, 2012, Pages 463-468

  Ware, Norma C ^a   Wyatt, Monique A ^a   Haberer, Jessica E ^b   Baeten, Jared M ^c   Kintu, Alexander ^d   Psaros, Christina ^b   Safren, Steven ^b   Tumwesigye, Elioda ^d   Celum, Connie L ^c   Bangsberg, David R ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Kabwohe Clinical Research Centre   (Uganda)

Author keywords

Adherence; HIV acquisition; HIV prevention; HIV serodiscordant couples; Pre exposure prophylaxis; PrEP

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PLACEBO; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GROUNDED THEORY; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; OPEN-ENDED QUESTIONNAIRE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROPHYLAXIS; QUALITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; UGANDA;

ADENINE; ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; ATTITUDE TO HEALTH; DEOXYCYTIDINE; FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; INTERPERSONAL RELATIONS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHOSPHONIC ACIDS; SEXUAL PARTNERS; UGANDA; YOUNG ADULT;

EID: 84859722634     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31824a060b     Document Type: Article

References (18)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide for the prevention of HIV Infection in women. Science. 2010;329:1168-1174.
2. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
3. Thigpen MC, Kebaabetswe PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 17-20, 2011; Rome, Italy. Abstract WELBC01.
4. Microbicide Trials Network. The VOICE Study: vaginal and oral interventions to control the epidemic. Microbicide Trials Network. 2011. Available at: http://www.mtnstopshiv.org/news/studies/mtn003/backgrounder. Accessed December 7, 2011.
5. Microbicide Trials Network. MTN statement on decision to discontinue use of tenofovir gel in VOICE, a major HIV prevention study in women. Microbicide Trials Network. 2011. Available at: http://www.mtnstop-shiv.org/node/3909. Accessed December 7, 2011.
6. Microbicide Trials Network. MTN Statement on Decision to Discontinue Use of Oral Tenofovir Tablets in VOICE, a Major HIV Prevention Study in Women. Microbicide Trials Network. 2011. Available at: http://www. mtnstopshiv.org/ node/3619. Accessed December 7, 2011
7. FHI 360. The FEM-PrEP Project Fact Sheet. FHI360. Available at: http://www.fhi360.org/NR/rdonlyres/evxkcdam56e3pbbodkmezujdjkeanl- q2uc7zvsbd2hv5wgkgrhq
8. 5kkaki5tyhsl5hdypbrcyvxptonc/FEMPrEPFactSheetAboutFEMPrEP. Pdf. Accessed November 29, 2011.
9. FHI 360. FHI Statement on the FEM-PrEP HIV Prevention Study. FHI to Initiate Orderly Closure of FEM-PrEP. FHI360 2011. Available at: http://www.fhi360.org/en/aboutfhi/media/releases/fem-prep-statement 041811.htm. Accessed November 29, 2011.
10. Baeten JM, Donnell D, Mujugira A, et al, for the Partners PrEP Study Team. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 17-20, 2011; Rome, Italy. Abstract MOAX0106.
11. Haberer J, Baeten J, Celum C, et al. Nearly perfect early adherence to antiretroviral pre-exposure prophylaxis (PrEP) against HIV infection among HIV-serodiscordant couples as determined by multiple measures: preliminary data from the Partners PrEP Study. Presented at: Conference on Retroviruses and Opportunistic Infections; February 2011; Boston, MA. Poster Presentation #488.
12. Patton MQ. Qualitative Research and Evaluation Methods. 3rd ed. Thousand Oaks, CA: Sage Publications; 2002.
13. Glaser BC, Strauss AL. The Discovery of Grounded Theory: Strategies for Qualitative Research. New York, NY: Aldiric de Gruyter; 1967.
14. Corbin J, Strauss A. Basics of Qualitative Research. Los Angeles, CA: Sage Publications; 2008.
15. Cairns G. Pre-exposure prophylaxis does work for women, two studies find. NAM AIDSMAP, HIV & AIDS-Sharing Knowledge, Changing Lives 2011. Available at: http://www.aidsmap.com/Pre-exposure-prophylaxis-does-work-for-women-two- studies-find/page/1879841. Accessed November 29, 2011.
16. Alcorn K. Tenofovir PrEP arm dropped in women's HIV prevention trial. NAM AIDSMAP, HIV & AIDS-Sharing Knowledge, Changing Lives 2011. Available at: http://www.aidsmap.com/page/2090698. Accessed November 20, 2011.
17. Karim SSA, Kashuba ADM, Werner L, et al. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: Implications for HIV prevention in women. Lancet. 2011;378:279-281.
18. Stirratt MJ, Gordon CM. Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep. 2008;5:186-192.